Radiotherapy and chemotherapy for gliomas.
This review summarizes papers published within the past year. The value of high-precision radiotherapy techniques, mainly interstitial radiotherapy, was confirmed by several studies. Despite encouraging preliminary results, demonstration of a benefit from radiosurgery and a direct comparison with brachytherapy must await a randomized study. Trials of 78 Gy of hyperfractionated radiotherapy have been disappointing. Interesting results were obtained with interstitial chemotherapy, and several studies found that second-line chemotherapy or immunotherapy regimens could be useful in recurrent gliomas.
Delattre
J Y
JY
Service de Neurologie, Hôpital de la Salpêtrière, Paris, France.
Uchuya
M
M
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy; D001918:Brachytherapy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D016371:Cranial Irradiation; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016634:Radiosurgery; D018714:Radiotherapy, Adjuvant
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D011838:Radiation-Sensitizing Agents